Global Bladder Cancer Market - Overview
The global market for bladder cancer is growing at a steady pace. This can be attributed to increasing prevalence of bladder cancer. It is reported that the exact cause of the bladder cancer is not clear, however, the medical condition is estimated to be aaocaited with certain factors which are inclusive mutations in the genetic composition of the patients, continuous exposure to harmful radiations, and adoption of unhealthy lifestyle. Such conditions are responsible for increasing the reported cases of bladder cancer across the globe. Moreover, factors such as increasing government support alongwith the growing investment in the research and development procees boosts the market growth. Adfditionally, rising awareness regarding the medical condition among the masses also contributs to the market growth. However, there factors such as high cost of the treatment in terms of expensive drugs, and related side effects are estimated to restarin the market tgrowth during the projected period.
Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/1899
Market Segmentation:
By type, the global bladder cancer market has been segmented into transitional cell bladder cancer, invasive bladder cancer, superficial bladder cancer, squamous cell bladder cancer, adenocarcinoma, and others.
By treatment, the bladder cancer market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and others.
By diagnosis, the global bladder cancer market has been segmented into urine lab tests, cystoscopy, biopsy, imaging tests, and others.
By end-user, the bladder cancer market is segmented into hospitals, clinics, cancer care centers, and others.
Regional Analysis:
By region, the global bladder cancer market has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is expected to retain a dominant position globally throughout the forecast period. The factors favoring the market growth in the region include the rising burden of bladder cancer, innovations in healthcare solutions, availability of advanced healthcare infrastructure, etc. Although the U.S. is estimated to grow at a relatively slower pace, it is still likely to account for a dominant share of the regional market.
Europe is expected to remain a highly lucrative market over the assessment period. The factors encouraging the market growth in the region are the availability of better healthcare solutions coupled with a rise in bladder cancer cases. Asia Pacific is anticipated to register a high growth rate owing to increasing awareness about bladder diseases and developments in treatments.
Global Bladder Cancer Market - Regional Analysis
On the basis of the geography, the global bladder cancer market is segmented into the four major regions, namely the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas holds the largest share in the global bladder cancer market. Presence of huge patient population suffering from bladder cancer is a major reason behind the same. As per the American Cancer Society, approximately 79,030 new cases of bladder cancer were reported in 2017. Moreover, it was estimated that the disease caused about 16,870 deaths withihn the U.S. Additionally, factors includfing changing lifestyle, rising government support, incrteasing role of cancer care organisations for incraesing the awareness s also impacts a positive growth in the global bladder cancer market.
Europe accounts for the second largest market share for the bladder cancer, which is followed by Asia Pacific. Asia Pacific is the fastest growing market owing to the huge population base, increasing prevalence of bladder cancer, rapidly developing economies and presence of huge opportunity for the growth of the market. The Middle East & Africa has the least market share due to the unavailability of the required healthcare infrastructure, lack of awareness among people, and affordability issues due to presence of the poor economies in Africa region.
Global Bladder Cancer Market - Competitive Analysis
The market for bladder cancer is well established market with number of companies operating in this market. There are large number of companies involved in the development of the products including the drugs, molecules.
Bladder Cancer Market is becoming huge with increasing demand for the treatment options. Unavailability of absolute treatment has given a wide range of platform for the development of the market. Companies are focusing on the development of new products which will be cost effective and will have minimum side effects. Various companies are involved in the development of specific types of molecules, and novel therapies. These companies have adapted the strategies of the acquisitions, and also launching of the new products in order to strive in this big and competitive market. Moreover, competition amongst new market players is also expected to upsurge growth for bladder cancer drugs market over the next few years.
In October 2017, Astellas and Seattle Genetics initiated pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer.
In May 2017, AstraZeneca plc received US FDA accelerated approval for the drug Imfinzi (durvalumab) which is to be used for previously treated patients with advanced bladder cancer.
In February 2017, Bristol-Myers Squibb received FDA approval for Opdivo (nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.
In April 2017, FDA granted Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer. It is the first and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy.
In May 2017, Eli Lily & company announced results of their drug Cyramza’s phase III clinical trial for Bladder cancer. According to company, Some 531 patients with urothelial carcinoma were treated in the trial, with a statistically significant improvement in progression-free survival. With this, Company received huge boost for the development of this drug in the treatment of bladder cancer.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Browse Complete Report with TOC @ https://www.marketresearchfuture.com/reports/bladder-cancer-market-1899
Read similar reports by Market Research Future
Dry Mouth Relief Market
Remdesivir (Covid 19) Market
Healthcare Claims Management Market
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
